DPP4 and heart failure: Nevertheless, one should underline that this is a very heterogeneous group of medications and some European Society for Heart Failure made clear discrepancy between saxagliptin that might increase risk of HF hospitalization and those DPP-4 inhibitors that have no impact on hospitalization (alogliptin, sitagliptin, vildagliptin, and linagliptin).